Login to Your Account



Other News To Note


Wednesday, September 5, 2012
• Cellerant Therapeutics Inc., of San Carlos, Calif., was awarded $36.4 million by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy to treat acute radiation syndrome (ARS). The third year of funding is part of a five-year BARDA award valued at up to $169.9 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription